# Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

> **NCT03896152** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 13 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** LNP023

## Key facts

- **NCT ID:** NCT03896152
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-05
- **Primary completion:** 2020-04-07
- **Final completion:** 2022-02-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03896152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03896152, "Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03896152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*